Introduction
Malaria is tropical infectious disease of humans and other animals caused by mosquito-borne parasites that include Plasmodium falciparum (Pf) and Plasmodium vivax (Pv). The former causes the greatest percentage of deaths due to its more severe symptoms. The disease is prevalent in tropical climates in the African and Asian sub-continents, affecting countries with less developed economies [1, 2] . In 2015 the World Health Organization (WHO) reported that approximately 5.9 million of children under five years of age died from this infectious disease [3] . To reduce the ongoing issue of drug resistance, the current frontline treatment artemisinin is given as a combination only, yet there are signs that its efficacy is under threat [4e6] . New antimalarial drugs that target novel modes of action are therefore highly desirable to tackle this disease [7e11].
The malaria parasite has a complex life cycle in which multiple kinase enzymes play an important role [12, 13] . The target of the artemisinin has recently been suggested to be phosphoinositide 3-kinase (PfPI3K) [14] , while the target of the MMV development compound MMV390048 was proposed to be phosphoinositide 4-kinase (PfPI4K) [15] . Additional protein kinases have also been implicated as possible targets [16e18] . A number of studies aimed at improving our understanding of the approximately 65 Pf specific kinases have been reported, many of which share considerable homology with human kinases [10, 16, 19] . This has led to a kinase screening campaign [20] and SAR studies on specific protein kinases, including PfCDPK1 [21, 22] , PfPK5 [23] and PfPK7 [24] . Nevertheless, it is not yet established which parasite kinase rep-resents the most valid target [10] , or whether polypharmacology approaches could represent a useful approach, as found for cancer [25] .
In 2010, GlaxoSmithKline reported the results of screening of almost 2 million compounds to identify anti-malarial hits. Approximately 13,500 compounds with activity at P. falciparum (Pf) 3D7, multidrug resistant Dd2 Pf strain and for cytotoxicity in the HepG2 cell line were released in the public domain [26] .In2016, these hits were re-assessed at five Pf kinases (PfCDPK1, PfCDPK4, PfPK6, PfPK7 and PfMAPK2) and led to the identification of twelve series with potential for optimization [20] .
Our separate analysis of the GSK screening data led to the identification of a cluster of 2,4-diaminopyrimidine compounds with good activity, efficiency, physical properties and synthetic tractability ( Table 1 ). The compounds display activity at the multidrug resistant Dd2 strain, whilst the HepG2 SAR suggests an anti-malarial vs. cytotoxicity window of 50 fold is achievable (Table 1) . 1b is a confirmed inhibitor of PfCDPK1 (0.012 mM), CDPK4 (0.089 mM) and PfPK6 (0.054 mM). Host kinase interactions also require consideration as these could either lead to cytotoxicity or also potentially facilitate parasite eradication [17, 27] .
The most probable human kinases targeted by 1aed include Janus kinase 2 (hJAK2) [28] and Aurora A hAURKA [29, 30] . Indeed, other hJAK and hAUR inhibitor classes have shown anti-malarial activity from repurposing studies [10, 31] . The 2,4-diaminopyrimidine chemotype also appears in Epidermal growth factor (hEGFR) [32] , and c-Jun N-terminal kinase (hJNK) [33] publications, as well as in patents targeting cancer-related pathways via hJAK [34] and hAURK ( Fig. 1) [35] . Kinase inhibitors offer great potential as antimalarials due to the wealth of chemical, biological and safety data amassed over many years to treat diseases in humans, potentially reducing the development burden.
In this study we report the design, synthesis and biological evaluation of new 2, 4-diaminopyrimidine compounds. Our goal is to improve our SAR understanding of this series by screening additional analogs at the drug-resistant K1 Pf strain in the belief that molecules which target either individual, or a defined subset of kinases, offer potential new approaches to kill resistant strains. We also assess the cytotoxicity of the series using monkey kidney epithelial cell line (Vero), and the adenocarcinomic human alveolar basal epithelial cell line (A549). The human kinase activity of a subset are also evaluated for their potential to inhibit the human protein kinases: JAK2, JAK3 and EGFR.
Results

Design
The mode of action of compounds 1aed is unconfirmed, how-ever PfCDPK1, hAUR, hJAK and EGFR are probable targets. A focused library of 2, 4-diamino-pyrimidines derivatives were prepared using established synthetic methods and directed towards improving our understanding the link between Pf activity, cytotoxicity and activity at key kinases in the hosts.
Crystal structures of the Plasmodium Berghei (Pb) CDPK1 homolog and the principal human targets were downloaded for analysis (Table 2) . Despite dramatic differences in sequence identity, the conserved ATP binding site means inhibitors can have considerably cross reactivity [10] . A key difference between these targets is the moderately sized, non-polar gatekeeper for the human proteins, compared to the smaller, more polar Thr sidechain [37] .
We have undertaken modification to the chemotype at four different positions as highlighted in Fig. 2. Region 1 exploits the difference at the gatekeeper while region 2 (pyrimidine 4 position) targets differences within the kinase backpocket [38] .
Modifications at the latter position have resulted in dramatic changes in the hAURA protein conformation though the flipping of the DFG-loop despite only subtle changes in substitution of the 4-position aniline [39] . Modifications at region 3 will induce subtle changes in ring conformation, which can benefit selectivity, while region 4 can be exploited to improve compound solubility [40] .
Anti-malarial SAR shows that compounds with R1 ¼ -CN have higher anti-malarial activity, however, this is mirrored by increases in the % cytotoxicity. We therefore evaluated the effect of incorporation of -H, -CN, -OMe and -CONH2. A range of substituted anilines at the 2-and 4-positions were selected to exploit interaction toward the kinase solvent pocket and backpocket, respectively, and maintain reasonable molecule properties (Table 3) . We attempted to bias the reagent selection to focus on lower MWT (mean ¼ 405 da) and clogP (mean ¼ 4.04). This was with the goal of increasing the likelihood of achieving better solubility and permeability and solubility, a pre-requisite for reliable phenotypic testing.
Synthesis
Intermediates were synthesized using the methodology described in Scheme 1. 2a was produced from the reaction of p-fluoronitrobenzene and piperazine in DMSO with the assistance of K2CO3. The amine product was hydrogenated to 3a using Pd/C and H2. Intermediates 3b & 3c were produced in the same manner.
Compound 1a was synthesized following Scheme 2. The Cl at the 4-position of 5-cyano-2,4-dichloropyrimidine was substituted by p-aminobenzamide with the assistance of DIPEA giving intermediate 4a (Scheme 2). Intermediate 4a was reacted at with 3a assisted of DIPEA, leading to substitution at the 2-position. Com-pounds 5aee were synthesized in an analogous manner to 1a. Compound 5e was oxidized using hydrogen peroxide to yield compound 5f. Compound 5g, having an -OMe substituent at the 5-position was synthesized using the same protocol as 1a [35] . Compounds 5her, with H at the 5-position, were synthesized as follows; nucleophilic substitution at the 4-position of 2,4-dichloro pyrimidine was achieved using DIPEA base for R2 ¼ 3-SO2NH2 and 3-CH3, a HCl promoted reaction for R2 ¼ 2-CONH2. Nucleophilic attack at the corresponding 2-position was achieved using TFA to promote the reaction.
Nineteen compounds were synthesized (Table 3 ) with reaction yields varied from low (<30%) to excellent (>90%). Among the 19 compounds synthesized, compounds 1a and 5j. 1a was originally reported in the study of Gamo et al. [26] and in the recent paper of Crothers et al. [20] The titled compounds 1a, 5aer were evaluated for their in vitro anti-malarial activity at the Pf K1 strain (EC50) using a hypoxanthine incorporation assay [42, 43] . The compounds show a range in potency from 0.43 to 8.97 mM. Compound 1a, 0.009 mM against the 3D7 strain, was found to be 3.9 mM at the resistant K1 strain. Compounds 5n and 5o were 0.65 and 0.43 mM respectively. In comparison, standards chloroquine displayed an activity 0.57 mM, Mefloquine 0.07 mM and artemisinin at 0.002 mM.
Systematic analysis of the results presented in Table 3 suggests that compounds with eH at R1 are preferred for anti-malarial activity (as exemplified by 5a,r). R2 position shows a preference for anilines with R2 ¼ 3-Me (5a,r) or 2-CONH2 (5k,m). The R3 position does not display a clear preference towards the substituents employed. R4 shows a general preference towards Mepiperazine, compared to morpholine or the simpler substituted anilines.
Cytotoxicity
Compounds 1a, 5aer were evaluated for their cytotoxicity at 10 mM against the Vero cell line (ATCC CCL-81) using the method described by Hunt and co-workers [44] . The compounds show a range in potency from 25 to 96%. A degree of correlation between activity and cytotoxicity, with the most potent compounds (5n,o) also displaying high (94%) cytotoxicity. This compares to 50% for chloroquine, a standard anti-malarial treatment. Compounds 5d, 5k and 5m display mM antimalarial activity and low to moderate cytotoxicity at 31, 66 and 35%, respectively.
Five compounds were taken forward for further assessment; potent but cytotoxic compounds (5n,o), moderately potent and cytotoxic compounds (5k), and moderately potent and weakly cytotoxic compounds (5d,m). EC50s against the Vero (ATCC CCL-81) and A549 (ATCC CCL-185) cells using an MTT based method (Table 4 ) [45] . The EC50s are in good agreement with the % cyto-toxicity data, with 5d,k & m demonstrating better activity than compounds 5n,o. The A549 cytotoxicity data broadly mirrors those obtained in the Vero cell line. The lower EC50 values would be consistent with the higher expression of certain kinases in this disease tissue [46e50] .
No clear SAR is apparent at the R1 and R2 positions. Hydrogen is preferred at the R3 position and -H and morpholine are preferred at the R4 position. Compounds 5k and 5m show a reasonable balance of anti-malarial activity and cytotoxicity, approaching the desired 50-fold window.
Protein kinase activity
Compounds 1a, 5aer were evaluated for their in vitro inhibition of human kinases JAK2, JAK3 and EGFR (Table 4) . Inhibition was determined by using an Antibody Beacon™ Tyrosine Kinase Assay Kit (A-35725; Invitrogen, USA). Compounds 5k,meo display sub mM inhibition at hJAK2 kinase, mM inhibition at hJAK3 and all compounds display >10 mM inhibition at hEGFR.
Compounds 5m and 5o, the most potent anti-malarials, but also the most cytotoxic of compounds are more active at the human kinases assessed. 5o is a confirmed inhibitor of all three protein kinases while compound 5n inhibits JAK2 at 0.05 mM. In contrast, 5d shows minimal inhibition of the kinases and also displays good cytotoxicity at both the Vero and A549 cell lines.
Inhibiting multiple Pf kinase targets without harming human cells will be a challenge, particularly since many kinase compounds come from human anti-cancer projects [20] . Yet, there is considerable safety and tolerability information in relation to kinase inhibition profiles that could be leveraged to develop molecules with a more targeted pharmacology. Furthermore, tackling host-parasite target interactions is also a feature of established DHFR anti-malarials. Methotrexate, a hDHFR inhibitor used in cancer treatment, also has potential as a PfDHFR anti-malarial if used at lower doses [51] .
Conclusions
We identified a series of diamino-pyrimidines anti-malarial from mining the screening data reported by GSK [26] . We per-formed the design, synthesis and testing of new analogs to reveal additional SAR with respect to the K1 strain, cytotoxicity at the Vero and A549 cell lines as well as inhibition at representative human kinases.
Sixteen new compounds have been synthesized and evaluated against the K1 resistant Pf strain. The compounds displayed activity comparable to chloroquine. We identified 5n and 5o as having submM anti-malarial activity. These compounds were also identified as being potent human kinase inhibitors as well as being cytotoxic. Compounds 5d and 5k were identified as mM inhibitors with improved cytotoxicity and human kinase selectivity.
Results suggest series has potential but further work needed to explore the strain dependence and maximize the anti-malarial/potency window. Additional work is required to establish the molecular target(s) of this compound class.
Experimental details
Chemistry
Reagents and solvents obtained from commercial suppliers were used without further purification.
All reactions were monitored by TLC aluminum/silica gel plate with UV light visualization. Column chromatography was performed using silica gel 60 (40e63 mm). 1H NMR spectra were recorded on both Varian instrument at 400 MHz and on a Bruker instrument at 500 MHz. Chemical shifts were reported in ppm (d) using the residual solvent line as the internal standard. Mass spectra (MS) were performed on Agilent 1100 HPLC instrument coupled to a LCjMSD Trap mass spectrometer, in ESI(þ) mode or APCI mode. Compounds showed a purity 95% as determined from the corresponding UV absorbance HPLC chromatogram.
Preparation of anilines 3aec
4.2.1. 3-Methyl-4-(4-methylpiperazin-1-yl)aniline (3a)
A mixture of 1-fluoro-2-methyl-4-nitro-benzene (3.22 mmol), 1-methylpiperazine (3.63 mmol) and potassium carbonate (3.83 mmol) in dimethyl sulfoxide (4 ml) were stirred and heated to 100 C for 4 h. The resultant reaction solution was cooled down to room temperature, added water (50 ml) to the reaction mixture, filtered off the solid residue, washed with water (50 ml), and air-dried to give the desired product of 1-methyl-4-(2-methyl-4-nitrophenyl-piperazine (2a) Afterwards, the obtained compound, 2a was hydrogenated. Pd/C (2.78 mmol) was added to a stirred solution of 1-methyl-4-(2-methyl-4-nitrophenyl-piperazine (5.53 mmol)) in methyl alcohol (15 ml) in N2 atmosphere. Following this it was hydrogenated overnight by maintaining the reaction flask in an atmosphere of H2 gas (balloon). The resultant was filtered thorough celite plate and concentrated under vacuum. The crude product was purified with silica-gel column chromatography A solution of 4-fluoronitrobenzene (7.1 mmol) and potassium carbonate (8.52 mol) in dimethyl sulfoxide (2 ml) was stirred at room temperature for 0.5 h 1-methylpiperazine (7.1 mmol) was added dropwise in the mixture solution. The resulting reaction mixture was stirred at room temperature for 6 h. The mixture was then poured into cold water. A yellow precipitate formed and was collected to A mixture of 1-bromo-4-nitrobenzene (5.0 mmol), morpholine (5.0 mol) and potassium carbonate (6.0 mmol) in dimethyl sulf-oxide (2 ml) were stirred and heated to 100 C for 7 h. The resultant reaction solution was allowed to cool to room temperature. The mixture solution was extracted with EtOAc. The organic layer was collected, washed with brine, dried over Na2SO4, filtered, and dried under reduced pressure. The crude product was purified with silica-gel column chromatography (30% EtOAc/hexane) to give the desired product of 4-(4-nitrophenyl)morpholine, 2c as a yellow 
General procedure for the preparation of intermediate compounds 4aee
DIPEA (0.86 mmol) was added to the solution of 2,4-dichloropyrimidine-5-carnonitrile (0.57 mmol) in DMF (0.5 ml) and stirred at room temperature for 10 min. A solution of aminobenzene reagent corresponding to desired product (0.57 mmol) in DMF (0.5 ml) was added dropwise to the reaction mixture and stirred for 1 h. The resultant was evaporated under vacuum and extracted with EtOAc. The organic layer was collected, washed with brine, dried over MgSO4, filtered, and dried under reduced pres-sure. 4c was obtained from the reaction of 4b, whereby substitution at the 2-position occurred.
2-[(2-Chloro-5-cyano-pyrimidin-4-yl)amino]benzamide (4a)
2-aminobenzamide is used as an aminobenzene reagent, fol-lowed the general procedure and purified by silica-gel column chromatography (25%EtOAc/hexane) to yield 4a as a yellow solid, yield 41%, 1H NMR (500 MHz, DMSO 
3-[(2-Chloro-5-cyano-pyrimidin-4-yl)amino] benzenesulfonamide (4b)
2-Aminobenzensulfonamide is used as an aminobenzene re-agent, followed the general procedure and purified by silica-gel column chromatography (10%EtOAc/hexane) to yield 4b as a beige solid, 
N-tert-butyl-3-[(2-chloro-5-cyano-pyrimidin-4-yl] benzenesulfonamide (4e)
N-t-butyl-3-aminobenesulfonamide is used as an amino-benzene reagent, followed the general procedure and purified by silica-gel column chromatography (0e5%MeOH/DCM) to yield 4e as a beige solid, yield 30%, 1H NMR (500 MHz, DMSO- 4.7. General procedure for the synthesis of compound 5eeg 4.7.1. 2,4-bis(3-methylanilino)pyrimidine-5-carbonitrile (5e) 3-Methylaniline (0.29 mmol) and DIPEA were added to a solu-tion of 2,4-dichloropyrimidine-5-carbonitrile (0.29 mmol) in DMF (5 ml). The reaction mixture was stirred at room temperature for 4.5 h. The reaction mixture was then extracted with EtOAc. The organic layer was collected, washed with brine, dried over MgSO4, filtered, and dried under reduced pressure to yield the desired product, 5e which disubstituted reaction at 2-and 4-position occurred, with a 50% yield as a white solid. 1H NMR (500 MHz, were combined in a round bot-tom flask with 5 ml of isopropanol and catalytic amounts of TFA. The reaction mixture was stirred at 80 C overnight. The reaction was then cooled down to room temperature, neutralized with 1 M NaOH, and evaporated under vacuum to give a crude product. The crude product was purified by silica-gel column chromatography to yield a desired product. 
